mouse antihuman cd14  (Bio-Rad)

Journal: Journal of cellular immunology

Article Title: Preliminary Evidence of Differentially Induced Immune Responses by Microparticle-adsorbed LPS in Patients with Crohn’s Disease

doi: 10.33696/immunology.4.152

Figure Lengend Snippet: Stimulation of PBMC with LPS, TiO 2 and CaCL 2 dose response curves in Crohn’s disease and healthy controls, as individual components of the LPS-TiO2-Ca 2+ conjugate.

Article Snippet: Following culture, cells were washed twice in TCM, prior to staining with mouse antihuman monoclonal CD14-FITC (Serotec, UK) in the residual cell suspension (200 μl cells in TCM) for 30 mins on ice in the dark.

Techniques:

Journal: Clinical and Developmental Immunology

Article Title: Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages

doi: 10.1155/2010/547179

Figure Lengend Snippet: Expression of the Mannose Receptor (MR) by human TAM. (a) Flow cytometry analysis of purified preparations of TAM from carcinoumatous ascites of patients with ovarian cancer. TAMs were stained with anti-CD206 mAb (clone PAM-1) or with anti-CD14. Twelve different preparations were tested. (b) Immunohistochemistry of 2 tumor samples from ovarian cancer tissues stained with anti-CD206 mAbs (clone PAM-1, upper panels; clone WE458, lower panels). Positive cells are brown stained (magnification: left panels 40 x, right panels 100 x).

Article Snippet: PE-mouse antihuman CD14 (clone M5E2) was purchased from (BD Pharmingen, Italy).

Techniques: Expressing, Flow Cytometry, Purification, Staining, Immunohistochemistry

Journal: Clinical and Developmental Immunology

Article Title: Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages

doi: 10.1155/2010/547179

Figure Lengend Snippet: Tumoral mucins induce the internalization of the MR: flow cytometry expression of the MR/CD206 (a) and CD14 (b). Two different TAM preparations (TAM1 and TAM2) and 2 M-CSF-differentiated normal macrophages (Macro1 and Macro2) were pretreated (30 min. room temperature) with 33% v/v ascitic fluid from ovarian tumor patients, prior to staining with anti-CD206 or CD14 mAbs. Results are shown as % of positive cells. (c) Purified TAMs were pretreated with unconjugated Dextran (1 mg/mL); mucin Tag-72 (200 IU/mL); mucin CA125 (20–200 IU/mL) prior to staining with anti-CD206 mAb. Results are shown as % relative to values of Mean fluorescence Intensity (MFI) of CD206 in control cells (medium) and are the mean +/− SD of 4 experiments with 4 different TAM preparations (3 TAM preparations for CA125). P < .05 (Student's t -tests).

Article Snippet: PE-mouse antihuman CD14 (clone M5E2) was purchased from (BD Pharmingen, Italy).

Techniques: Flow Cytometry, Expressing, Staining, Purification, Fluorescence

Journal: Animals : an open access journal from MDPI

Article Title: MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.

doi: 10.3390/ani12162135

Figure Lengend Snippet: Figure 1. Representative dot plots depicting the gating strategy of canine peripheral blood leukocytes. (A) Forward scatter (FSC-hight) vs. side scatter (SSC-hight) dot plot showing leukocyte populations (population colors result from the regions set on the cytogram C); (B) debris and non-cellular elements were eliminated by setting a region defining CD45+ leukocytes (R1) on the SSC vs. CD45:APC dot plot; (C) leukocyte populations “(R1)” were analyzed on the CD45:APC/CD14:FITC dot plot in order to separate CD14+ monocytes (R2—red color) from lymphocytes (R3—blue color).

Article Snippet: Samples were labeled with the following panel of monoclonal antibodies: rat anti-dog CD45 APC-conjugated (clone YKIX716.13, Bio-Rad, Hercules, CA, USA), mouse anti-dog CD11b unconjugated (clone CA16.3E10, Bio-Rad), rat anti-dog MHC class II FITC-conjugated (clone YKIX334.2; Bio-Rad) and mouse antihuman CD14 FITC or Alexa Fluor®647-conjugated (clone TÜK4; Bio-Rad) that cross-reacts with canine CD14 molecules [21].

Techniques:

Journal: Animals : an open access journal from MDPI

Article Title: MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.

doi: 10.3390/ani12162135

Figure Lengend Snippet: Figure 2. Representative dot plots depicting gating strategy of peripheral blood monocytes of dog with lymphoma. (A) Regions were set for all CD11b+ myeloid cells (R1) and for CD14+ monocytes (R2) on the CD14:APC vs. CD11b:PE double fluorescence dot plot; (B) distribution of all leukocytes (CD11b+ cells—red color) and (C) monocytes (from the R2 region—blue color) according to the expression of CD14 and MHCII. Bottom-row dot plots show isotype controls, separate for each Ab: anti-CD14 (A,B) and anti-MHCII (C). Controls allowed us to set the quadrants.

Article Snippet: Samples were labeled with the following panel of monoclonal antibodies: rat anti-dog CD45 APC-conjugated (clone YKIX716.13, Bio-Rad, Hercules, CA, USA), mouse anti-dog CD11b unconjugated (clone CA16.3E10, Bio-Rad), rat anti-dog MHC class II FITC-conjugated (clone YKIX334.2; Bio-Rad) and mouse antihuman CD14 FITC or Alexa Fluor®647-conjugated (clone TÜK4; Bio-Rad) that cross-reacts with canine CD14 molecules [21].

Techniques: Expressing

Journal: Animals : an open access journal from MDPI

Article Title: MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.

doi: 10.3390/ani12162135

Figure Lengend Snippet: Figure 3. (A) The percentage of CD11b+CD14+ monocytes: MHCII+ and MHCII−, in the peripheral blood of healthy dogs (n = 11) and dogs with lymphoma: not receiving any drugs (NRG, n = 10) and receiving glucocorticoids (RG, n = 8). Arithmetic mean ± standard deviation. Significant differences between the percentage of MHCII+ and MHCII−monocytes among each group: # p < 0.05, ### p ≤0.001 (Wilcoxon) and for the percentage of MHCII+ or MHCII−monocytes in comparison to healthy dogs: *** p ≤0.001 (no significant differences between dogs with lymphoma NRG and RG) (Kruskal–Wallis and post hoc Dunn analysis). (B) The results are shown as the ratio of CD11b+CD14+ monocyte percentages: MHCII+ to MHCII−. Arithmetic mean ± standard deviation. Significant differences between groups: *** p ≤0.001 (Kruskal–Wallis and post hoc Dunn analysis).

Article Snippet: Samples were labeled with the following panel of monoclonal antibodies: rat anti-dog CD45 APC-conjugated (clone YKIX716.13, Bio-Rad, Hercules, CA, USA), mouse anti-dog CD11b unconjugated (clone CA16.3E10, Bio-Rad), rat anti-dog MHC class II FITC-conjugated (clone YKIX334.2; Bio-Rad) and mouse antihuman CD14 FITC or Alexa Fluor®647-conjugated (clone TÜK4; Bio-Rad) that cross-reacts with canine CD14 molecules [21].

Techniques: Standard Deviation, Comparison

Journal: Animals : an open access journal from MDPI

Article Title: MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.

doi: 10.3390/ani12162135

Figure Lengend Snippet: Figure 4. The number of CD14+ monocytes in the peripheral blood of healthy dogs (n = 11) and dogs with lymphoma: not receiving any drugs (NRG, n = 10) and receiving glucocorticoids (RG, n = 8). (A) Total number of CD14+ monocytes per microliter of peripheral blood. The number of CD14+ cells was calculated based on their percentage in relation to all leukocytes (CD45+ cells) and white blood cell count. (B) The number of MHCII+ and (C) MHCII−monocyte subsets. Arithmetic mean ± standard deviation. Significant differences between groups: * p < 0.05, ** p ≤0.01, *** p ≤0.001 (Kruskal–Wallis and Dunn post hoc analysis). (D) The numbers of all evaluated cell populations in individual patients: MHCII−and MHCII+ monocytes as well as all CD14+ cell population.

Article Snippet: Samples were labeled with the following panel of monoclonal antibodies: rat anti-dog CD45 APC-conjugated (clone YKIX716.13, Bio-Rad, Hercules, CA, USA), mouse anti-dog CD11b unconjugated (clone CA16.3E10, Bio-Rad), rat anti-dog MHC class II FITC-conjugated (clone YKIX334.2; Bio-Rad) and mouse antihuman CD14 FITC or Alexa Fluor®647-conjugated (clone TÜK4; Bio-Rad) that cross-reacts with canine CD14 molecules [21].

Techniques: Cell Counting, Standard Deviation

Journal: Asian Journal of Andrology

Article Title: Human umbilical cord Wharton's jelly-derived mesenchymal stem cell transplantation could improve diabetic intracavernosal pressure

doi: 10.4103/aja.aja_33_21

Figure Lengend Snippet: Validation of hWJ-MSCs by flow cytometry. Flow cytometry showed that hWJ-MSCs expressed high levels of matrix markers (CD44, CD90, and CD105) but low amounts of hematopoietic lineage markers (CD14, CD34, CD45, and CD19) and HLA-DR. hWJ-MSCs: human umbilical cord Wharton's jelly-derived mesenchymal stem cells; HLA-DR: human leukocyte antigen DR.

Article Snippet: A total of 1 × 10 5 cells were washed with 2% FBS in phosphate-buffered saline (PBS; washing buffer) and resuspended in washing buffer containing mouse antihuman CD90, CD44, CD105, CD14, CD19, CD34, CD45, and human leukocyte antigen DR (HLA-DR) antibodies (1:100 dilution; eBioscience, Waltham, MA, USA).

Techniques: Biomarker Discovery, Flow Cytometry, Derivative Assay